Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| diagnostic agents, gadolinium derivatives | 4558 | 80529-93-7 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see PENTETIC ACID), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706)
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 2, 1988 | FDA | BAYER HLTHCARE |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Nephrogenic systemic fibrosis | 134.71 | 44.28 | 23 | 523 | 4085 | 90623816 |
| Contrast media deposition | 91.42 | 44.28 | 10 | 536 | 56 | 90627845 |
| Gadolinium deposition disease | 57.18 | 44.28 | 7 | 539 | 115 | 90627786 |
| Urticaria | 44.67 | 44.28 | 26 | 520 | 312708 | 90315193 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Nephrogenic systemic fibrosis | 64.42 | 59.30 | 12 | 245 | 3489 | 42617589 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Nephrogenic systemic fibrosis | 180.74 | 40.77 | 32 | 822 | 5451 | 110582994 |
| Contrast media deposition | 102.54 | 40.77 | 12 | 842 | 100 | 110588345 |
| Hyperintensity in brain deep nuclei | 69.04 | 40.77 | 9 | 845 | 192 | 110588253 |
| Urticaria | 63.70 | 40.77 | 36 | 818 | 318821 | 110269624 |
| Contrast media allergy | 61.53 | 40.77 | 12 | 842 | 3411 | 110585034 |
| Contrast media reaction | 52.99 | 40.77 | 10 | 844 | 2388 | 110586057 |
| Gadolinium deposition disease | 44.88 | 40.77 | 6 | 848 | 156 | 110588289 |
| Pruritus | 41.91 | 40.77 | 35 | 819 | 581525 | 110006920 |
None
| Source | Code | Description |
|---|---|---|
| ATC | V08CA01 | VARIOUS CONTRAST MEDIA MAGNETIC RESONANCE IMAGING CONTRAST MEDIA Paramagnetic contrast media |
| FDA MoA | N0000175862 | Magnetic Resonance Contrast Activity |
| FDA EPC | N0000180184 | Paramagnetic Contrast Agent |
| MeSH PA | D003287 | Contrast Media |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:37335 | MRI contrast agent |
None
None
None
None
None
None
None
| ID | Source |
|---|---|
| D01707 | KEGG_DRUG |
| 4019578 | VUID |
| N0000179141 | NUI |
| 86050-77-3 | SECONDARY_CAS_RN |
| 4019578 | VANDF |
| CHEBI:31797 | CHEBI |
| CHEMBL1200431 | ChEMBL_ID |
| RH248G8V27 | UNII |
| DB00789 | DRUGBANK_ID |
| 25486 | RXNORM |
| 4772 | MMSL |
| 6030 | MMSL |
| d01451 | MMSL |
| 000676 | NDDF |
| 004527 | NDDF |
| 710811005 | SNOMEDCT_US |
| C0060934 | UMLSCUI |
| D019786 | MESH_DESCRIPTOR_UI |
| 55466 | PUBCHEM_CID |
| 5396 | INN_ID |
| RH248G8V27 | INXIGHT DRUGS |
None